Provided by Tiger Trade Technology Pte. Ltd.

Phio Pharmaceuticals

1.18
-0.0300-2.48%
Post-market: 1.180.00000.00%19:12 EDT
Volume:138.32K
Turnover:166.11K
Market Cap:13.71M
PE:-0.88
High:1.24
Open:1.24
Low:1.17
Close:1.21
52wk High:4.19
52wk Low:0.8127
Shares:11.62M
Float Shares:11.55M
Volume Ratio:0.56
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3423
EPS(LYR):-1.4535
ROE:-113.71%
ROA:-65.77%
PB:1.09
PE(LYR):-0.81

Loading ...

Company Profile

Company Name:
Phio Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2003
Employees:
6
Office Location:
411 Swedeland Road,Suite 23-1080,King of Prussia,Pennsylvania,United States
Zip Code:
19406
Fax:
- -
Introduction:
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Directors

Name
Position
Robert J. Bitterman
Chair of the Board and Chief Executive Officer and Director and President
David H. Deming
Independent Director and Lead Independent Director
Curtis A. Lockshin
Director
Jonathan E. Freeman
Director
Patricia A. Bradford
Director
R. Todd Plott
Director

Shareholders

Name
Position
Robert J. Bitterman
Chair of the Board and Chief Executive Officer and Director and President
Lisa C. Carson
Chief Financial Officer and Vice President, Finance and Administration